Alpha 2.0
Login Register
» Authors » Paul Fitzpatrick

Paul Fitzpatrick

Explore the profile of Paul Fitzpatrick including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 26
Citations 323
Followers 0
Related Specialties
Oncology
Biochemistry
Molecular Biology
Top 10 Co-Authors
Goran Landberg
Anders Stahlberg
Raymond C Stevens
Lin Wang
Christineh N Sarkissian
Charles R Scriver
Pernilla Gregersson
Donal Landers
Alejandra Gamez
Jeffrey F Lemontt
Published In
BMJ Open
Arch Toxicol
Mol Genet Metab
Philos Trans A Math Phys Eng Sci
Arch Biochem Biophys
Affiliations
Soon will be listed here.
Recent Articles
1.
Mechanistic safety assessment via multi-omic characterisation of systemic pathway perturbations following in vivo MAT2A inhibition
Fogal V, Michopoulos F, Jarnuczak A, Hamza G, Harlfinger S, Davey P, et al.
Arch Toxicol . 2024 May; 98(8):2589-2603. PMID: 38755480
The tumour suppressor p16/CDKN2A and the metabolic gene, methyl-thio-adenosine phosphorylase (MTAP), are frequently co-deleted in some of the most aggressive and currently untreatable cancers. Cells with MTAP deletion are vulnerable...
2.
An International Comparison of Presentation, Outcomes and CORONET Predictive Score Performance in Patients with Cancer Presenting with COVID-19 across Different Pandemic Waves
Wysocki O, Zhou C, Rogado J, Huddar P, Shotton R, Tivey A, et al.
Cancers (Basel) . 2022 Aug; 14(16). PMID: 36010932
Patients with cancer have been shown to have increased risk of COVID-19 severity. We previously built and validated the COVID-19 Risk in Oncology Evaluation Tool (CORONET) to predict the likely...
3.
Establishment of CORONET, COVID-19 Risk in Oncology Evaluation Tool, to Identify Patients With Cancer at Low Versus High Risk of Severe Complications of COVID-19 Disease On Presentation to Hospital
Lee R, Wysocki O, Zhou C, Shotton R, Tivey A, Lever L, et al.
JCO Clin Cancer Inform . 2022 May; 6:e2100177. PMID: 35609228
Purpose: Patients with cancer are at increased risk of severe COVID-19 disease, but have heterogeneous presentations and outcomes. Decision-making tools for hospital admission, severity prediction, and increased monitoring for early...
4.
Biomarker identification using dynamic time warping analysis: a longitudinal cohort study of patients with COVID-19 in a UK tertiary hospital
Burke H, Freeman A, ORegan P, Wysocki O, Freitas A, Dushianthan A, et al.
BMJ Open . 2022 Feb; 12(2):e050331. PMID: 35168965
Objectives: COVID-19 is a heterogeneous disease, and many reports have described variations in demographic, biochemical and clinical features at presentation influencing overall hospital mortality. However, there is little information regarding...
5.
Pharmacological inhibition of MERTK induces in vivo retinal degeneration: a multimodal imaging ocular safety assessment
Hamm G, Maglennon G, Williamson B, Macdonald R, Doherty A, Jones S, et al.
Arch Toxicol . 2022 Jan; 96(2):613-624. PMID: 34973110
The receptor tyrosine kinase, MERTK, plays an essential role in homeostasis of the retina via efferocytosis of shed outer nuclear segments of photoreceptors. The Royal College of Surgeons rat model...
6.
Wave comparisons of clinical characteristics and outcomes of COVID-19 admissions - Exploring the impact of treatment and strain dynamics
Freeman A, Watson A, ORegan P, Wysocki O, Burke H, Freitas A, et al.
J Clin Virol . 2021 Nov; 146:105031. PMID: 34844145
Objectives: Dexamethasone has now been incorporated into the standard of care for COVID-19 hospital patients. However, larger intensive care unit studies have failed to show discernible improvements in mortality in...
7.
Patient-derived scaffolds influence secretion profiles in cancer cells mirroring clinical features and breast cancer subtypes
Persson E, Gregersson P, Gustafsson A, Fitzpatrick P, Rhost S, Stahlberg A, et al.
Cell Commun Signal . 2021 Jun; 19(1):66. PMID: 34090457
Background: Breast cancer is a common malignancy with varying clinical behaviors and for the more aggressive subtypes, novel and more efficient therapeutic approaches are needed. Qualities of the tumor microenvironment...
8.
Research Evaluation Alongside Clinical Treatment in COVID-19 (REACT COVID-19): an observational and biobanking study
Burke H, Freeman A, Dushianthan A, Celinski M, Batchelor J, Phan H, et al.
BMJ Open . 2021 Jan; 11(1):e043012. PMID: 33483446
Introduction: The COVID-19 pandemic caused by SARS-CoV-2 places immense worldwide demand on healthcare services. Earlier identification of patients at risk of severe disease may allow intervention with experimental targeted treatments,...
9.
Characterization of cell-free breast cancer patient-derived scaffolds using liquid chromatography-mass spectrometry/mass spectrometry data and RNA sequencing data
Landberg G, Jonasson E, Gustafsson A, Fitzpatrick P, Isakson P, Karlsson J, et al.
Data Brief . 2020 Jul; 31:105860. PMID: 32637480
Patient-derived scaffolds (PDSs) generated from primary breast cancer tumors can be used to model the tumor microenvironment . Patient-derived scaffolds are generated by repeated detergent washing, removing all cells. Here,...
10.
Biosimilar infliximab administration for the management of acute graft-versus-host disease
Tollkuci E, Fitzpatrick P, Seddon A, Myers R, Nathan S, Ustun C
J Oncol Pharm Pract . 2020 May; 26(8):2047-2051. PMID: 32356680
Introduction: Acute graft-versus-host disease (aGVHD) is a significant immune-mediated complication of allogeneic hematopoietic stem cell transplant (HSCT). Despite prophylactic immunosuppression, the incidence of grades II-IV aGVHD post-HSCT varies from 20...